Free Trial

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo

GNCAQ vs. VRPX, NEXI, SCPS, VAXX, ARDS, NAVB, EVLO, SMFL, CMRA, and GNCA

Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Virpax Pharmaceuticals (VRPX), NexImmune (NEXI), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Smart for Life (SMFL), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry.

Genocea Biosciences vs. Its Competitors

Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Genocea Biosciences N/A N/A N/A

Virpax Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Genocea Biosciences Neutral

Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Virpax Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Genocea Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Genocea Biosciences beats Virpax Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GNCAQ vs. The Competition

MetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6K$298.66M$5.70B$10.42B
Dividend YieldN/AN/A5.78%4.69%
P/E RatioN/AN/A75.6726.39
Price / SalesN/A515.00540.28125.20
Price / CashN/A22.4425.6730.68
Price / BookN/A10.2012.826.40
Net IncomeN/A-$111.61M$3.29B$276.69M

Genocea Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
VRPX
Virpax Pharmaceuticals
0.1516 of 5 stars
$0.01
+9.9%
N/A-99.9%$15KN/A0.007
NEXI
NexImmune
N/A$0.01
flat
N/A-99.9%$14KN/A0.0070
SCPS
Scopus BioPharma
N/A$0.00
flat
N/A+0.0%$13KN/A0.009
VAXX
Vaxxinity
N/A$0.00
flat
N/A-50.0%$13KN/A0.0090
ARDS
Aridis Pharmaceuticals
N/A$0.00
-84.6%
N/AN/A$11KN/A0.0030Gap Down
NAVB
Navidea Biopharmaceuticals
N/A$0.00
-80.0%
N/A-80.0%$10K$8.13K0.0010Gap Down
EVLO
Evelo Biosciences
N/A$0.00
flat
N/AN/A$9KN/A0.00120
SMFL
Smart for Life
N/A$0.00
-90.0%
N/A-93.2%$7K$11.11M0.00110Gap Up
CMRA
Comera Life Sciences
N/A$0.00
flat
N/AN/A$6K$1.00M0.002Gap Down
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070

Related Companies and Tools


This page (NASDAQ:GNCAQ) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners